Dogwood Therapeutics
DWTXDogwood Therapeutics is a development-stage biopharmaceutical company dedicated to creating non-opioid treatments for chronic pain and neuropathy.
Earnings
Next report
Aug 12, 2026 (In 3 weeks)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Dogwood Therapeutics is a development-stage biopharmaceutical company dedicated to creating non-opioid treatments for chronic pain and neuropathy. The company's core value proposition centers on its proprietary Nav1.7 sodium channel modulation platform, which aims to address significant unmet medical needs in chemotherapy-induced neuropathic pain. By targeting specific ion channels, the company seeks to provide durable pain relief without the safety risks associated with traditional opioid therapies.
A clinical-stage developer of first-in-class non-opioid analgesics targeting the Nav1.7 channel for chemotherapy-induced pain.
Questions, answered.
- What is Dogwood Therapeutics's market cap?
- Dogwood Therapeutics (DWTX) has a market capitalization of $46.1M and trades on XNAS.
- Who are Dogwood Therapeutics's competitors?
- Dogwood Therapeutics's key competitors include Vertex Pharmaceuticals, Eli Lilly and Company, Pfizer Inc., and others. These companies compete in similar markets and product categories.
- Who does Dogwood Therapeutics partner with?
- Dogwood Therapeutics's notable partners include National Cancer Institute.
- What subsidiaries does Dogwood Therapeutics have?
- Dogwood Therapeutics's subsidiaries include Pharmagesic (Holdings) Inc., Wex Pharmaceuticals, Inc., IWT Bio, Inc., and others.
- Where is Dogwood Therapeutics headquartered?
- Dogwood Therapeutics is headquartered in United States of America and employs approximately 4 people. It has been publicly traded since 2020.